Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDG30Q)

• Drug Name: VOB560 Drug Info
• Synonyms: S 65487

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]
Multiple myeloma	2A83	Phase 1	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMDG30Q

Molecule-Related Drug Atlas

Drug(s) Targeting Apoptosis regulator Bcl-2 (BCL-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MCI-186	DM8ZHP1	Amyotrophic lateral sclerosis	8B60.0	Approved	[3]
Taxol	DMUOT9V	Breast cancer	2C60-2C65	Approved	[4]
GDC-0199	DMH0QKA	Chronic lymphocytic leukaemia	2A82.0	Approved	[5]
ABT-263	DMNE56X	Myelofibrosis	2A20.2	Phase 3	[6]
Taxol/Paraplatin/Herceptin	DML6GAN	Breast cancer	2C60-2C65	Phase 3	[7]
Oblimersen	DM7KI4E	Melanoma	2C30	Phase 3	[8]
RG7601	DMDVAFP	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[5]
Thymoquinone	DMVDTR2	Polycystic ovarian syndrome	5A80.1	Phase 2/3	[9]
Obatoclax	DMPF9ZM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
PI-88/Taxotere	DM4FIWC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04702425) VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma). U.S. National Institutes of Health.
• [2] Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020 May 21;9(5):1287.
• [3] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [4] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [5] ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.
• [6] Clinical pipeline report, company report or official report of Roche (2009).
• [7] Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
• [8] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [9] Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
• [10] Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
• [11] Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7.